Pancreatic Cancer Research

ResearcherAichi Cancer CenterActive in the last 2 years

Shoji Kawakatsu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6692-552X; OpenAlex author ID A5054548406. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 2 papers

Papers 9

  1. Close correlation between patients' positive mood and postoperative complication burden in hepato-biliary-pancreatic cancer: a prospective comparative cohort t… Co-author DOI 10.1016/j.hpb.2025.07.015↗
  2. FAM111B Suppression Enhances Sensitivity to Gemcitabine in Pancreatic Cancer Through Intracellular pH Regulation. Co-author DOI 10.1111/cas.70212↗
  3. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  4. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  5. Prognostic Significance of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: A Single-Center Experience and Systemat… Co-author DOI 10.1245/s10434-022-11722-x↗
  6. ASO Author Reflections: Positive Status of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: Are They Candidates for… Co-author DOI 10.1245/s10434-022-11747-2↗
  7. Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04203-2↗
  8. Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety. Co-author DOI 10.1007/s11605-018-3995-3↗
  9. Encapsulating fibrosis following neoadjuvant chemotherapy is correlated with outcomes in patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0222155↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shunsuke Onoe · 3 shared papers, 2023–2025 · strength 0.61
  2. Junpei Yamaguchi · 2 shared papers, 2025 · strength 0.47
  3. Masaki Sunagawa · 2 shared papers, 2025 · strength 0.47
  4. Tomoki Ebata · 2 shared papers, 2025 · strength 0.47
  5. Yosuke Inoue · 4 shared papers, 2019–2023 · strength 0.42
  6. Waki Hosoda · 2 shared papers, 2022 · strength 0.35
  7. Keitaro Matsuo · 2 shared papers, 2022 · strength 0.35
  8. Akio Saiura · 3 shared papers, 2019–2020 · strength 0.29
  9. Sohei Satoi · 2 shared papers, 2023 · strength 0.27
  10. Tsuyoshi Hayashi · 2 shared papers, 2023 · strength 0.27
  11. Hidetoshi Eguchi · 2 shared papers, 2023 · strength 0.27
  12. Yoshito Tomimaru · 2 shared papers, 2023 · strength 0.27
  13. Yoshifumi Takeyama · 2 shared papers, 2023 · strength 0.27
  14. Akihiro Ohba · 2 shared papers, 2023 · strength 0.27
  15. Yuichi Nagakawa · 2 shared papers, 2023 · strength 0.27
  16. Michiaki Unno · 2 shared papers, 2023 · strength 0.27
  17. Toshio Kokuryo · 1 shared paper, 2025 · strength 0.25
  18. Taisuke Baba · 1 shared paper, 2025 · strength 0.25
  19. Motonobu Nishimura · 1 shared paper, 2025 · strength 0.25
  20. Yukihiro Yokoyama · 1 shared paper, 2025 · strength 0.22
  21. Yutaka Takazawa · 2 shared papers, 2019–2020 · strength 0.20
  22. Yoshihiro Ono · 2 shared papers, 2019–2020 · strength 0.19
  23. Takeaki Ishizawa · 2 shared papers, 2019–2020 · strength 0.19
  24. Hiromichi Ito · 2 shared papers, 2019–2020 · strength 0.19
  25. Yu Takahashi · 2 shared papers, 2019–2020 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.